Published in Proc Natl Acad Sci U S A on April 15, 1992
Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet (2001) 2.03
Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet (2000) 1.69
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet (1997) 1.68
Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc (1999) 1.67
Prostate cancer: 3. Individual risk factors. CMAJ (1998) 1.66
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet (2000) 1.64
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet (1998) 1.63
Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet (2012) 1.62
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet (2000) 1.58
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev (2006) 1.35
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet (1999) 1.30
Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet (1996) 1.26
Risk factors for prostate cancer. Rev Urol (2002) 1.21
Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer (2003) 1.19
A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet (2001) 1.16
Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate (2008) 1.12
Screening for prostate cancer. West J Med (1995) 1.12
In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet (1999) 1.10
Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum Genet (2007) 1.10
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer (1997) 1.10
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Prostate cancer: 2. Natural history. CMAJ (1998) 1.06
A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet (2000) 1.05
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer (2000) 1.05
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet (2000) 1.04
Risk factors for prostate cancer. Nat Clin Pract Urol (2009) 1.03
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion. Am J Hum Genet (1999) 0.99
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev (2010) 0.98
Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Hum Genet (2006) 0.96
Psychological and screening profiles of first-degree relatives of prostate cancer patients. J Behav Med (2001) 0.96
Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet (2009) 0.94
Hereditary aspects of prostate cancer. CMAJ (1995) 0.94
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer (1999) 0.93
Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet (2001) 0.93
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. Hum Genet (2005) 0.91
Prostate cancer progression. Implications of histopathology. Am J Pathol (1994) 0.91
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer (2002) 0.89
Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci U S A (2004) 0.89
ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies. Prostate Cancer Prostatic Dis (2010) 0.89
Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer (1998) 0.89
Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23. Hum Genet (2003) 0.88
Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol (2008) 0.87
Clinical features of familial or hereditary prostate cancer in korean men: a pilot study. Korean J Urol (2011) 0.87
Krüppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol (2003) 0.86
Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol (2008) 0.86
Relationship between the Glutathione-S-Transferase P1, M1, and T1 Genotypes and Prostate Cancer Risk in Korean Subjects. Korean J Urol (2011) 0.85
Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet (2007) 0.84
Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet (2001) 0.83
Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect (1999) 0.83
Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer. Pharmgenomics Pers Med (2014) 0.83
Association between single nucleotide polymorphisms on chromosome 17q and the risk of prostate cancer in a Chinese population. Chin J Cancer (2011) 0.83
Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate (2008) 0.82
Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer (2009) 0.82
Occult prostate cancer effects the results of case-control studies due to verification bias. Anticancer Res (2008) 0.82
Admixture mapping of prostate cancer in African Americans participating in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate (2013) 0.81
Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. PLoS One (2015) 0.81
Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). J Cancer (2013) 0.80
HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl (2016) 0.80
Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis. Eur J Hum Genet (2012) 0.80
Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostatic Dis (2013) 0.79
Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Fam Cancer (2012) 0.79
Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Semin Radiat Oncol (2016) 0.79
A genetic-based approach to personalized prostate cancer screening and treatment. Curr Opin Urol (2015) 0.79
Inherited predisposition to prostate cancer. Eur J Epidemiol (2003) 0.79
Genetics of prostate cancer. Clin Med Res (2003) 0.79
The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc (2000) 0.79
Molecular epidemiology studies of cancer in families. Br J Cancer (1993) 0.79
The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Fam Cancer (2006) 0.79
Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett (2008) 0.79
Polyphenols from the mangosteen (Garcinia mangostana) fruit for breast and prostate cancer. Front Pharmacol (2013) 0.78
Genetic susceptibility to prostate cancer: a review. Fam Cancer (2003) 0.78
Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer (2014) 0.77
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet (2012) 0.76
The clinical genetics of prostate cancer. Hered Cancer Clin Pract (2004) 0.75
CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog (2016) 0.75
Metastatic Adenocarcinoma of Prostate in a 28-Year-Old Male: The outcome is poor in young patients? Indian J Palliat Care (2015) 0.75
Prostate cancer: risk assessment and diagnostic approaches. Rev Urol (2001) 0.75
Epidemiology of Prostate and Testicular Cancer. Semin Intervent Radiol (2016) 0.75
Systematic meta-analyses of gene-specific genetic association studies in prostate cancer. Oncotarget (2016) 0.75
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA (2015) 0.75
No evidence of linkage to chromosome 1q42.2-43 in 131 prostate cancer families from the ACTANE consortium. Anglo, Canada, Texas, Australia, Norway, EU Biomed. Br J Cancer (2000) 0.75
Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett (2017) 0.75
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin. Hered Cancer Clin Pract (2007) 0.75
A general model for the genetic analysis of pedigree data. Hum Hered (1971) 40.17
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Identification and characterization of the familial adenomatous polyposis coli gene. Cell (1991) 14.46
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science (1991) 9.89
Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet (1991) 7.87
The molecular genetics of cancer. Science (1987) 7.64
Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (1987) 6.93
Hereditary cancer, oncogenes, and antioncogenes. Cancer Res (1985) 5.12
Ascertainment in the sequential sampling of pedigrees. Clin Genet (1977) 4.71
Structural evidence for the authenticity of the human retinoblastoma gene. Science (1987) 4.67
Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol (1990) 4.60
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (1988) 4.15
Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res (1989) 3.35
Sampling considerations in the gathering and analysis of pedigree data. Am J Hum Genet (1979) 3.32
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Genetic epidemiology of breast cancer: segregation analysis of 200 Danish pedigrees. Genet Epidemiol (1984) 3.11
Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science (1988) 2.83
Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst (1990) 2.72
Regressive logistic models for familial disease and other binary traits. Biometrics (1986) 2.70
Cancer. A deadly inheritance. Nature (1991) 2.66
Efficiency and robustness of pedigree segregation analysis. Am J Hum Genet (1978) 2.60
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res (1991) 2.14
General models for segregation analysis. Am J Hum Genet (1975) 2.04
Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting". Proc Natl Acad Sci U S A (1988) 2.03
Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst (1987) 2.02
Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A (1990) 1.82
An investigation of the familial aspects of carcinoma of the prostate. Cancer (1960) 1.75
Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer (1991) 1.61
The ninth Gordon Hamilton-Fairley memorial lecture. Hereditary cancers: clues to mechanisms of carcinogenesis. Br J Cancer (1989) 1.22
Age of onset, age at examination, and other covariates in the analysis of family data. Genet Epidemiol (1989) 1.20
Age at onset and causes of disease. Perspect Biol Med (1986) 1.09
Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate (1985) 0.98
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Human disease genes. Nature (2001) 5.31
Human genetics teaching in U.S. medical schools. Am J Hum Genet (1981) 5.30
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Genetic counseling: a consumers' view. N Engl J Med (1972) 3.90
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science (1994) 3.57
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Preliminary evidence for genetic anticipation in Crohn's disease. Lancet (1996) 3.32
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet (1998) 3.00
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
X-linked hypoxanthine-guanine phosphoribosyl transferase deficiency: heterozygote has two clonal populations. Science (1968) 2.69
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Use of robust variance components models to analyse triglyceride data in families. Ann Hum Genet (1985) 2.52
Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology (1996) 2.50
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol (1988) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Genetics in the medical curriculum. Am J Med Genet (1982) 2.31
Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol (1994) 2.28
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
The effect of Mendelian disease on human health: a measurement. Am J Med Genet (1985) 2.18
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Risk factors in schizophrenia. Season of birth, gender, and familial risk. Br J Psychiatry (1992) 1.81
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab (1968) 1.78
Evidence that autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet (1986) 1.74
Tay-Sachs screening: motives for participating and knowledge of genetics and probability. Am J Hum Genet (1976) 1.74
A robust identity-by-descent procedure using affected sib pairs: multipoint mapping for complex diseases. Hum Hered (2001) 1.70
The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol (1982) 1.70
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol (1998) 1.69
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Genetic susceptibility of benign prostatic hyperplasia. J Urol (1994) 1.66
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Report of the Task Force on Teaching Human Genetics in North American Medical Schools. Am J Hum Genet (1989) 1.65
Application of transmission disequilibrium tests to nonsyndromic oral clefts: including candidate genes and environmental exposures in the models. Am J Med Genet (1997) 1.65
Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol (1984) 1.63
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol (1979) 1.63
Association study of transforming growth factor alpha (TGF alpha) TaqI polymorphism and oral clefts: indication of gene-environment interaction in a population-based sample of infants with birth defects. Am J Epidemiol (1995) 1.62
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
I. Feature article: Genetics for medical students. Am J Hum Genet (1987) 1.59
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol (1985) 1.58
Cavernous nerve grafts restore erectile function in denervated rats. J Urol (1991) 1.57
Genetics of nonsyndromic oral clefts revisited. Cleft Palate Craniofac J (1996) 1.57
Perspectives in the teaching of human genetics. Adv Hum Genet (1987) 1.57
Cancer control following anatomical radical prostatectomy: an interim report. J Urol (1991) 1.55
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.54
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Idiopathic retroperitoneal fibrosis. J Urol (1979) 1.53
Photo quiz. Clin Infect Dis (1995) 1.52
Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol (2000) 1.52
X-linked 6-phosphogluconate dehydrogenase in drosophila: subunit associations. Science (1965) 1.52
Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: evidence from Afro-Caribbean and Caucasian populations. Genomics (1996) 1.51
Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study on the genetics of asthma. Am J Hum Genet (2001) 1.50
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol (1998) 1.50
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
The effect of genetic susceptibility on causal inference in epidemiologic studies. Am J Epidemiol (1987) 1.48
Phenotypic discordance in a family with monozygotic twins and non-syndromic cleft lip and palate. Am J Med Genet (1996) 1.47
Genetic-epidemiologic study of omphalocele and gastroschisis: evidence for heterogeneity. Am J Med Genet (1992) 1.46
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology (1994) 1.45
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
Applications of the concept of attributable fraction in medical genetics. Am J Med Genet (1991) 1.45
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
Robust inference for variance components models in families ascertained through probands: I. Conditioning on proband's phenotype. Genet Epidemiol (1987) 1.44
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol (1989) 1.43
Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. Mol Psychiatry (2003) 1.42
Impact of anatomical radical prostatectomy on urinary continence. J Urol (1991) 1.41
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet (2001) 1.40
Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer (1991) 1.39
Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am (1990) 1.38
Impaired pulmonary function as a risk factor for mortality. Am J Epidemiol (1982) 1.38